UNSPSC 51313213: Bamipine lactate

This classification denotes a histamine-1 receptor antagonist C19H24N2.C3H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K8KNJ07D8, chemically known as propanoic acid, 2-hydroxy-, compd. with 1-methyl-n-phenyl-n-(phenylmethyl)-4-piperidinamine (1:1), but more generally known as bamipine lactate, which bears US NIH Compound Identifier 11462853. European Medicines Agency schedules Bamipine lactate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00663MIG.

Most nations, for tariff and trade purposes, schedule bamipine lactate under HS 29333999 and SITC 51574. As of Q4 2014, BAMIPINE LACTATE remains US FDA's Preferred Term for this commodity. Bamipine lactate bears US NLM identifiers UMLS ID C0771814 and NCI Concept Code C97686. SMILES: CC(C(=O)O)O.CN1CCC(CC1)N(CC2CCCCC2)C3CCCCC3.

UNSPSC 51313213 Bamipine lactate, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. The three most recent opportunities tagged under this code—a Seminole County IFB for naloxone and drug deactivation systems, a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescriptions, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—involve bulk pharmaceutical purchasing, supply-chain logistics, and pharmacy benefit management rather than bamipine lactate specifically. State and local buyers pursuing this code appear to be health departments, state human services agencies, and cooperative purchasing consortia acquiring prescription medications, over-the-counter products, and overdose-reversal supplies through wholesaler networks and direct manufacturer relationships, with compliance requirements including FDA registration, Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, and proof of legal authorization to work in the United States.

Recent activity spans Florida, Texas, and Minnesota, with the MMCAP procurement notably extending to Oregon through cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023, awarded on a fixed-fee basis with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer program without a formal evaluation timeline, designed to inform future RFP development. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, establishing multi-year contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with vendor pricing weighted at 75 percent of evaluation score and a 3 percent administrative fee on all purchases. The code shows activity but the recent solicitations do not support bamipine lactate as a material category in current state and local pharmaceutical procurement.